Trial Profile
A Retrospective Study Assessing the Clinical Outcomes of Everolimus in Patients with Neuroendocrine Prostate Cancer (NEPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 15 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.